ONCS Insider Trading (OncoSec Medical)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.71%

Insider Buying (Last 12 Months): $29,961,451.65

Insider Selling (Last 12 Months): $725,043.04

OncoSec Medical Insider Trading History Chart

OncoSec Medical Share Price & Price History

^$5.71

▲ +0.21 (3.82%)

As of 03/1/2021 01:00 AM ET

Days: 30 | 90 | 365

Biden Era Puts Spotlight on Green-Energy Profit-Stocks

From Resource Stock Digest | Ad

With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $0.25 per share, that’s advancing the largest green-energy asset in an entire country.

More Here...

OncoSec Medical Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/1/2021	Daniel J O'connor	CEO	Sell	3,413	$7.71	$26,314.23	99,269
1/25/2021	Grand Pharmaceutical & H China	Major Shareholder	Buy	4,067,037	$5.45	$22,165,351.65
11/20/2020	Alpha Holdings, Inc.	Director	Sell	80,000	$4.92	$393,600.00	1,350,001
11/18/2020	Alpha Holdings, Inc.	Director	Sell	10,999	$5.24	$57,634.76	1,480,001
11/16/2020	Alpha Holdings, Inc.	Director	Sell	40,000	$5.41	$216,400.00
11/2/2020	Daniel J O'connor	CEO	Sell	3,280	$3.79	$12,431.20	102,682
8/19/2020	Grand Pharmaceutical & H China	Major Shareholder	Buy	2,398,800	$3.25	$7,796,100.00
7/31/2020	Daniel J O'connor	CEO	Sell	3,133	$4.20	$13,158.60	105,962
4/30/2020	Daniel J O'connor	CEO	Sell	3,075	$1.79	$5,504.25	62,986
1/31/2020	Daniel J O'connor	CEO	Sell	2,654	$1.96	$5,201.84	66,061
1/16/2020	Sara Bonstein	CFO	Sell	1,351	$2.08	$2,810.08	41,389
10/31/2019	Daniel J O'connor	CEO	Sell	2,128	$2.16	$4,596.48	68,715
10/16/2019	Sara Bonstein	CFO	Sell	1,111	$2.01	$2,233.11	42,740
7/16/2019	Alpha Holdings, Inc.	Director	Buy	90,000	$2.30	$207,000.00
5/22/2019	Alpha Holdings, Inc.	Director	Buy	491,000	$3.14	$1,541,740.00	10,491,000
11/20/2018	James M Demesa	Director	Buy	8,500	$0.82	$6,970.00	14,001
11/7/2018	Daniel J O'connor	CEO	Buy	10,000	$0.91	$9,100.00	26,667
11/7/2018	James M Demesa	Director	Buy	1,500	$0.91	$1,365.00	14,001
7/5/2018	Avtar S Dhillon	Director	Sell	37,575	$1.39	$52,229.25	181,002
7/5/2018	Richard B Slansky	CFO	Sell	84,984	$1.39	$118,127.76	255,000
6/29/2018	Punit Dhillon	Director	Sell	5,401	$1.38	$7,453.38	355,702
6/29/2018	Richard B Slansky	CFO	Sell	2,420	$1.38	$3,339.60	255,000
6/27/2018	Punit Dhillon	Director	Sell	17,480	$1.37	$23,947.60	355,702
6/27/2018	Richard B Slansky	CFO	Sell	7,832	$1.37	$10,729.84	255,000
6/25/2018	Punit Dhillon	Director	Sell	1,021	$1.41	$1,439.61	355,702
6/25/2018	Richard B Slansky	CFO	Sell	458	$1.41	$645.78	255,000
6/22/2018	Punit Dhillon	Director	Sell	14,976	$1.42	$21,265.92	355,702
6/22/2018	Richard B Slansky	CFO	Sell	6,710	$1.42	$9,528.20	255,000
6/20/2018	Punit Dhillon	Director	Sell	55,585	$1.42	$78,930.70	355,702
6/20/2018	Richard B Slansky	CFO	Sell	24,906	$1.42	$35,366.52	255,000
6/18/2018	Punit Dhillon	Director	Sell	28,145	$1.39	$39,121.55	355,702
6/18/2018	Richard B Slansky	CFO	Sell	12,613	$1.39	$17,532.07	255,000

SEC Filings (Institutional Ownership Changes) for OncoSec Medical (NASDAQ:ONCS)

4.15% of OncoSec Medical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

OncoSec Medical Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/16/2021	One68 Global Capital LLC	22,261	$0.14M	0.3%	N/A	0.080%
2/16/2021	Price T Rowe Associates Inc. MD	11,400	$74K	0.0%	-33.2%	0.041%
2/16/2021	Avidity Partners Management LP	1,952,000	$12.59M	0.4%	N/A	6.974%
2/16/2021	ExodusPoint Capital Management LP	18,854	$0.12M	0.0%	N/A	0.067%
2/12/2021	Sandbox Financial Partners LLC	75,000	$0.48M	0.4%	N/A	0.268%
2/11/2021	Northern Trust Corp	27,310	$0.18M	0.0%	+94.9%	0.098%
2/10/2021	Renaissance Technologies LLC	318,906	$2.06M	0.0%	-20.8%	1.139%
2/9/2021	Sigma Planning Corp	32,802	$0.21M	0.0%	-26.0%	0.117%
2/5/2021	BlackRock Inc.	60,526	$0.39M	0.0%	+109.1%	0.216%
1/30/2021	Salzhauer Michael	27,303	$0.18M	0.1%	-15.5%	0.098%
12/11/2020	Virtu Financial LLC	10,167	$34K	0.0%	N/A	0.036%
11/19/2020	Schonfeld Strategic Advisors LLC	27,900	$95K	0.0%	N/A	0.100%
11/17/2020	Schonfeld Strategic Advisors LLC	27,900	$94K	0.0%	N/A	0.101%
11/6/2020	BlackRock Inc.	28,941	$98K	0.0%	-45.7%	0.105%
11/3/2020	Sigma Planning Corp	44,302	$0.15M	0.0%	-8.3%	0.160%
8/10/2020	D.A. Davidson & CO.	118,500	$0.24M	0.0%	+74.9%	0.515%
7/31/2020	Sigma Planning Corp	48,302	$99K	0.0%	+75.6%	0.210%
5/1/2020	Sigma Planning Corp	27,502	$35K	0.0%	N/A	0.121%
2/13/2020	Renaissance Technologies LLC	198,519	$0.36M	0.0%	+116.5%	1.853%
2/10/2020	Salzhauer Michael	32,303	$58K	0.0%	+127.5%	0.302%
11/6/2019	Salzhauer Michael	14,200	$28K	0.0%	N/A	0.133%
11/5/2019	D.A. Davidson & CO.	24,000	$47K	0.0%	N/A	0.225%
8/14/2019	Citadel Advisors LLC	13,073	$33K	0.0%	N/A	0.123%
8/14/2019	Worth Venture Partners LLC	39,241	$99K	0.1%	N/A	0.370%
8/14/2019	Vanguard Group Inc.	174,640	$0.44M	0.0%	-81.3%	1.645%
8/14/2019	Private Advisor Group LLC	10,500	$27K	0.0%	N/A	0.099%
8/13/2019	BlackRock Inc.	32,568	$82K	0.0%	-93.2%	0.307%
8/13/2019	Northern Trust Corp	11,441	$29K	0.0%	-90.0%	0.108%
8/7/2019	JPMorgan Chase & Co.	18,085	$46K	0.0%	N/A	0.170%
2/15/2019	Millennium Management LLC	40,051	$26K	0.0%	-43.0%	0.062%
2/13/2019	Geode Capital Management LLC	388,688	$0.25M	0.0%	+72.5%	0.603%
2/12/2019	Northern Trust Corp	114,921	$73K	0.0%	+33.6%	0.178%
2/11/2019	Moloney Securities Asset Management LLC	50,000	$32K	0.0%	+117.4%	0.078%
2/11/2019	Bank of New York Mellon Corp	100,325	$64K	0.0%	+484.1%	0.156%
2/8/2019	BlackRock Inc.	485,983	$0.31M	0.0%	+98.2%	0.753%
11/15/2018	Nexthera Capital LP	1,388,824	$1.94M	0.4%	-46.9%	2.345%
11/15/2018	Point72 Asset Management L.P.	1,825,985	$2.56M	0.0%	-17.6%	3.083%
9/17/2018	683 Capital Management LLC	300,000	$0.41M	0.0%	N/A	0.573%
8/15/2018	Millennium Management LLC	1,195,315	$1.65M	0.0%	+19.5%	2.283%
8/15/2018	Nexthera Capital LP	2,614,297	$3.61M	0.6%	+26.6%	4.994%
8/14/2018	Point72 Asset Management L.P.	2,215,000	$3.06M	0.0%	-31.1%	4.231%
8/14/2018	DRW Securities LLC	180,000	$0.25M	0.0%	+157.1%	0.344%
8/9/2018	BlackRock Inc.	238,940	$0.33M	0.0%	+1,303.5%	0.456%
5/16/2018	Millennium Management LLC	1,000,576	$1.88M	0.0%	+2,073.8%	1.944%
5/16/2018	Nexthera Capital LP	2,064,297	$3.88M	0.6%	N/A	4.010%
5/15/2018	Point72 Asset Management L.P.	3,215,000	$6.04M	0.0%	+47.5%	6.245%
5/15/2018	venBio Select Advisor LLC	4,007,696	$7.53M	0.4%	N/A	7.785%
5/15/2018	Sofinnova Ventures Inc	66,965	$0.13M	0.0%	N/A	0.130%
5/14/2018	DRW Securities LLC	70,000	$0.13M	0.0%	N/A	0.136%
5/14/2018	Commonwealth Equity Services LLC	76,510	$0.14M	0.0%	+97.6%	0.149%
2/16/2018	J. Goldman & Co LP	100,000	$0.16M	0.0%	N/A	0.233%
2/15/2018	Sabby Management LLC	153,137	$0.25M	0.0%	-84.8%	0.357%
2/14/2018	Deutsche Bank AG	160,759	$0.26M	0.0%	N/A	0.374%
2/13/2018	Renaissance Technologies LLC	167,093	$0.27M	0.0%	N/A	0.389%
2/13/2018	MYDA Advisors LLC	89,000	$0.15M	0.1%	N/A	0.207%
5/15/2017	Sabby Management LLC	975,839	$1.26M	0.1%	-16.9%	4.676%
2/13/2017	Renaissance Technologies LLC	95,000	$0.12M	0.0%	-39.6%	0.481%
8/15/2016	Sabby Management LLC	608,052	$1M	0.1%	-45.3%	3.448%
5/13/2016	Sabby Management LLC	1,111,348	$2.83M	0.1%	-9.2%	6.549%
5/13/2016	Renaissance Technologies LLC	43,400	$0.11M	0.0%	N/A	0.256%
5/13/2016	Geode Capital Management LLC	57,031	$0.15M	0.0%	No Change	0.336%
2/16/2016	Ridgeback Capital Investments L.P.	1,292,614	$3.06M	13.2%	N/A	7.617%
1/13/2016	Gierl Augustine Investment Management	200	$0	0.0%	N/A	0.001%

Data available starting January 2016

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.

Today's Range

Now: $5.71

$5.51

$5.78

50 Day Range

MA: $6.77

$5.50

$7.71

52 Week Range

Now: $5.71

$1.04

$8.16

Volume

322,013 shs

Average Volume

354,546 shs

Market Capitalization

$159.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.64

Who are the company insiders with the largest holdings of OncoSec Medical?

OncoSec Medical's top insider shareholders include:

Alpha Holdings, Inc (Director)
Daniel J O'connor (CEO)
Sara Bonstein (CFO)
Grand Pharmaceutical & H China (Major Shareholder)

Who are the major institutional investors of OncoSec Medical?

OncoSec Medical's top institutional shareholders include:

Avidity Partners Management LP — 6.97%
Renaissance Technologies LLC — 1.14%
Sandbox Financial Partners LLC — 0.27%
BlackRock Inc. — 0.22%
Sigma Planning Corp — 0.12%
Northern Trust Corp — 0.10%

Which major investors are selling OncoSec Medical stock?

Within the last quarter, ONCS stock was sold by these institutional investors:

Renaissance Technologies LLC
Sigma Planning Corp
Price T Rowe Associates Inc. MD
Salzhauer Michael

During the previous year, company insiders that have sold OncoSec Medical company stock include:

Alpha Holdings, Inc (Director)
Daniel J O'connor (CEO)

Which major investors are buying OncoSec Medical stock?

In the last quarter, ONCS stock was purchased by institutional investors including:

Avidity Partners Management LP
Sandbox Financial Partners LLC
BlackRock Inc.
One68 Global Capital LLC
ExodusPoint Capital Management LP
Northern Trust Corp

In the previous year, these company insiders have bought OncoSec Medical stock:

Alpha Holdings, Inc (Director)
Daniel J O'connor (CEO)